"Advanced practice providers are uniquely positioned to advocate for an individualized approach to patient care through shared decision-making," writes Adele M. Caruso, DNP, CRNP.
"I'm not opposed to making a profit, and certainly businesses that take the risk to develop new technology should be financially rewarded for bringing that technology to market. But should life-changing technology be limited to those who can pay?" ponders Dr. Rosevear.
In women with mixed urinary incontinence, a combined conservative and surgical treatment approach provided significant improvements versus surgical treatment alone.
Among patients with a clinical response 1 month after implantation, most went on to have clinically and statistically significant reductions in overactive bladder symptoms at 1 year.
Organizations representing urologists are urging Congress to enact protections from medical liability lawsuits for medical professionals who volunteer during emergencies, such as natural disasters or other large-scale crises.
Men with large prostates experience more relief from BPH with treatment by Aquablation therapy (using the AquaBeam System) than with transurethral resection of the prostate, researchers say.
A 69-year-old woman was transferred from an outside institution to our inpatient service with recurrent gross hematuria. Two weeks prior to transfer, she underwent routine bilateral ureteral stent exchange, which was complicated by gross hematuria with significant clot burden.
In this interview, Thomas Chi, MD, discusses how he performs PCNL, explains why he uses ultrasound instead of fluoroscopy, and offers advice to urologists looking to gain more experience with the procedure.
In this Urology Times Q&A, Jessica Nelson, MPAS, PA-C, past president of the Urological Association of Physician Assistants, offers a physician assistant’s perspective on PAs performing urologic procedures, PA training, and more.
Treatment with apalutamide (Erleada) resulted in a rapid and substantial decline in PSA, and greater magnitude of PSA decline correlated with improvement in several oncologic endpoints, results from the phase III SPARTAN study showed.